SCHEMBL16287166

SCHEMBL16287166

Cn1c(=O)c(-c2c(Cl)cccc2Cl)cc2c(N)nc(Nc3ccc(Br)cc3)nc21

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SRC P12931 14/20 0.62
▸ PDGFRB P09619 9/20 0.62
▸ PDGFRA P16234 9/20 0.62
▸ ABL1 P00519 8/20 0.62
▸ MAPK14 Q16539 8/20 0.62
▸ KIT P10721 3/20 0.62
▸ FGFR1 P11362 11/20 0.58
▸ EGFR P00533 6/20 0.58
▸ WEE1 P30291 3/20 0.57
▸ FGFR2 P21802 2/20 0.57
▸ FGFR4 P22455 2/20 0.57
▸ FGFR3 P22607 2/20 0.57
▸ PSEN1 P49768 1/20 0.55
▸ PSEN2 P49810 1/20 0.55
▸ APH1B Q8WW43 1/20 0.55
▸ NCSTN Q92542 1/20 0.55
▸ APH1A Q96BI3 1/20 0.55
▸ PSENEN Q9NZ42 1/20 0.55
▸ RIPK2 O43353 1/20 0.54
▸ ACVR1 Q04771 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16287869 0.92 SRC (0.73) SRCPDGFRBPDGFRAABL1MAPK14
SCHEMBL16287539 0.91 WEE1 (0.69) SRCPDGFRBPDGFRAABL1MAPK14
SCHEMBL16287371 0.85 SRC (0.74) SRCPDGFRBPDGFRAABL1MAPK14
SCHEMBL11939526 0.82 FGFR1 (0.84) SRCPDGFRBPDGFRAABL1MAPK14
SCHEMBL16995179 0.82 WEE1 (0.69) SRCPDGFRBPDGFRAABL1MAPK14
SCHEMBL16287053 0.82 SRC (0.69) SRCPDGFRBPDGFRAABL1MAPK14
SCHEMBL16287072 0.81 SRC (0.59) SRCPDGFRBPDGFRAABL1MAPK14
SCHEMBL16986361 0.79 FGFR1 (0.59) SRCPDGFRBPDGFRAABL1MAPK14
SCHEMBL16287461 0.79 FGFR1 (0.66) SRCPDGFRBPDGFRAABL1MAPK14
SCHEMBL16995184 0.79 FGFR1 (0.67) SRCPDGFRBPDGFRAABL1MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9630962-B2 4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof HOSPITAL CLINIC DE BARCELONA (ES) 2017-04-25 — — US claimed
EP-3008063-B1 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF INST QUÍMIC DE SARRIÁ CETS FUNDACIÓ PRIVADA (ES) 2017-04-19 — — EP claimed
US-20160176866-A1 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ, PRIVADA (ES) 2016-06-23 — — US claimed
EP-3008063-A1 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF Institut Químic de Sarriá CETS Fundació Privada (ES) 2016-04-20 — — EP claimed
WO-2015118110-A1 PYRIDO[2,3-D]PYRIMIDINE-7(8H)-ONE DERIVATIVES FOR THE TREATMENT OF HEPATITIS C INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ PRIVADA (ES) 2015-08-13 — — WO claimed
EP-2905024-A1 Pyrido[2,3-d]pyrimidine-7(8H)-one derivatives for the treatment of infections caused by Flaviviridae Institut Quimic De Sarriá Cets, Fundació Privada (ES) 2015-08-12 — — EP claimed
WO-2014198960-A1 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ PRIVADA (ES) 2014-12-18 — — WO claimed
EP-2813504-A1 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof Institut Quimic De Sarriá Cets, Fundació Privada (ES) 2014-12-17 — — EP claimed
US-9630962-B2 4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof HOSPITAL CLINIC DE BARCELONA (ES) 2017-04-25 — — US disclosed
US-9630962-B2 4-amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof HOSPITAL CLINIC DE BARCELONA (ES) 2017-04-25 — — US disclosed
EP-3008063-B1 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF INST QUÍMIC DE SARRIÁ CETS FUNDACIÓ PRIVADA (ES) 2017-04-19 — — EP disclosed
EP-3008063-B1 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO(2,3-D)PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF INST QUÍMIC DE SARRIÁ CETS FUNDACIÓ PRIVADA (ES) 2017-04-19 — — EP disclosed
US-20160176866-A1 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ, PRIVADA (ES) 2016-06-23 — — US disclosed
US-20160176866-A1 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ, PRIVADA (ES) 2016-06-23 — — US disclosed
EP-2905024-A1 Pyrido[2,3-d]pyrimidine-7(8H)-one derivatives for the treatment of infections caused by Flaviviridae Institut Quimic De Sarriá Cets, Fundació Privada (ES) 2015-08-12 — — EP disclosed
EP-2905024-A1 Pyrido[2,3-d]pyrimidine-7(8H)-one derivatives for the treatment of infections caused by Flaviviridae Institut Quimic De Sarriá Cets, Fundació Privada (ES) 2015-08-12 — — EP disclosed
WO-2014198960-A1 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ PRIVADA (ES) 2014-12-18 — — WO disclosed
WO-2014198960-A1 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF INSTITUT QUÍMIC DE SARRIÁ, CETS FUNDACIÓ PRIVADA (ES) 2014-12-18 — — WO disclosed
EP-2813504-A1 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof Institut Quimic De Sarriá Cets, Fundació Privada (ES) 2014-12-17 — — EP disclosed
EP-2813504-A1 4-Amino-6-(2,6-dichlorophenyl)-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8H)-one derivatives, synthesis and uses thereof Institut Quimic De Sarriá Cets, Fundació Privada (ES) 2014-12-17 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160176866-A1 4-AMINO-6-(2,6-DICHLOROPHENYL)-2-(PHENYLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES, SYNTHESIS AND USES THEREOF BCL6, BCL9, BCL3 SRC 1641/4885PDGFRB 904/4885PDGFRA 651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback